Loading stock data…
$2.57-0.13 (-4.81%)
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States.
NRx Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.57 with a market capitalization of $129M. Wall Street consensus targets $38.50 (4 analysts), implying a +1398.1% move over the next 12 months. The stock is currently 49% below its 52-week high of $5.05, remaining 13.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.10M↑ | $1.07M↑ | $983,000↑ | $242,000 | $0 |
| Gross Profit | $426,000↓ | $437,000↓ | $575,000↑ | $145,000 | $0 |
| Operating Income | -$6.50M↓ | -$4.75M↓ | -$4.62M↓ | -$4.02M↓ | -$3.73M |
| Net Income | -$16.52M↓ | -$1.43M↓ | $360,000↑ | -$5.89M↑ | -$17.58M |
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United ...